With Less low - dosage density of 2 μ g / mm 2

Clinicians want to have an effective drug-coated balloon (DCB) that is flexible and has good trackability and pushability to be delivered to the lesion. In addition, particulate embolization and loss of drug in transition are important factors that should be minimized. Arterial healing also plays a key role because in some patients, it may be necessary to shorten dual-antiplatelet therapy. If the same level of efficacy can be delivered with less drug, that would certainly be helpful, but this needs to be proven. Not all DCBs are created equal. In general, paclitaxelcoated balloons offer the greatest efficacy so far, and there seems to be agreement that balloons with excipient coating technology offer greater efficacy. Within this group, however, there is tremendous variability with respect to efficacy in drug transfer, drug loss, and particulate. The crystallinity of the coating plays a very important role in paclitaxel-coated balloons and the uniformity of drug coating. The higher the crystallinity, the greater the drug uptake for DCBs. Smallto medium-sized paclitaxel crystals stick to the injured vessel surface and continuously release paclitaxel over time into the underlying tissue. With regard to how the coating technology affects durability, many factors are involved, such as the drying process, coating on a folded versus an inflated balloon, crystallinity, ultrastructure, etc. To improve restenosis rates, the drug should remain resident in the tissue for at least 3 months, and the most important factors that seem to improve or worsen drug residency in the tissue are the level of crystallinity and the degree of injury. n ENDURACOATTM TECHNOLOGY Spectranetics’ proprietary EnduraCoatTM Technology limits drug loss during transit and facilitates efficient drug delivery with a Not All DCBs Are Created Equal